Effects of viral virulence on intrauterine growth in SIV-infected fetal Rhesus macaques (Macaca mulatta)

Article Abstract:

The amount of growth retardation among fetuses with HIV infection may depend on when during pregnancy the fetus becomes infected with HIV and on the potency of the virus. Researchers infected 26 monkey fetuses with two types of the simian immunodeficiency virus, which is similar to HIV, at different stages of the pregnancies. They found that all monkey fetuses infected with the stronger virus showed evidence of growth retardation and blood abnormalities, but fetuses infected early in the second trimester experienced the most severe effects. These fetuses had low amounts of growth-inducing substances. Fetuses infected with the weaker virus did not experience growth delays. These findings may be applicable to human infants with HIV and growth retardation.

Fetus, Growth, Pregnancy, HIV infection in pregnancy, Fetal development

---

Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS

Article Abstract:

Rhesus macaques mucosally inoculated with simian HIV (SHIV), a virus similar to HIV in humans, rapidly progress to an AIDS-like syndrome if they do not mount a rapid immunologic response to the virus. Researchers introduced SHIV rectally, vaginally, and intravenously to primates, and found that animals who produced antibodies against the virus had a slower progression of disease. Inoculation through mucous membranes produced a peak viral load in 14 days, compared to seven days in macaques infected intravenously, reflecting viral transit through the lymph system to the bloodstream.

Physiological aspects, Development and progression, HIV (Viruses), HIV, Viremia

---

Administration of 9-[2-(R)-(phosphonomethoxy) propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies

Article Abstract:

The experimental research drug PMPA appears to be effective in reducing the risk of HIV transmission during pregnancy but it has severe side effects. Researchers gave the drug to pregnant rhesus monkeys infected with simian immunodeficiency virus (SIV), the monkey equivalent of HIV. The drug was transported across the placenta and appeared in fetal blood 1 to 3 hours later. It reduced blood levels of the virus in the fetus and improved their outcome after birth. However, many had restricted growth and bone toxicity from the drug.

Models, Diseases, Rhesus monkey

Similar abstracts:

• Abstracts: The effectiveness of video-based interventions in promoting condom acquisition among STD clinic patients. Reductions in STD infections subsequent to an STD clinic visit: using video-based patient education to supplement provider interactions
• Abstracts: Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine
• Abstracts: Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells
• Abstracts: Participation of international medical graduates in graduate medical education and hospital care for the poor
• Abstracts: Contribution of biofilm bacteria to the contamination of the dental unit water supply. Molecular techniques reveal high prevalence of Legionella in dental units

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.